Natera, Inc. (NTRA)

NASDAQ: NTRA · Real-Time Price · USD
169.03
-0.31 (-0.18%)
Sep 3, 2025, 11:47 AM - Market open
-0.18%
Market Cap23.20B
Revenue (ttm)1.96B
Net Income (ttm)-253.24M
Shares Out 137.25M
EPS (ttm)-1.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume347,799
Open169.90
Previous Close169.34
Day's Range168.98 - 170.72
52-Week Range110.57 - 183.00
Beta1.76
AnalystsStrong Buy
Price Target193.50 (+14.48%)
Earnings DateAug 7, 2025

About NTRA

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissu... [Read more]

Sector Healthcare
IPO Date Jul 2, 2015
Employees 4,434
Stock Exchange NASDAQ
Ticker Symbol NTRA
Full Company Profile

Financial Performance

In 2024, Natera's revenue was $1.70 billion, an increase of 56.75% compared to the previous year's $1.08 billion. Losses were -$190.43 million, -56.20% less than in 2023.

Financial Statements

Analyst Summary

According to 16 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $193.5, which is an increase of 14.48% from the latest price.

Price Target
$193.5
(14.48% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability

For my first rating of Natera, I called it a buy, while today's consensus seems to be between a hold and a strong buy. Both proven revenue growth and expected future growth outlooks are upside drivers...

21 hours ago - Seeking Alpha

Natera Provides Update on Patent Litigation with NeoGenomics

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGe...

5 days ago - Business Wire

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ra...

6 days ago - Business Wire

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Associatio...

9 days ago - Business Wire

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers feat...

12 days ago - Business Wire

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These ...

12 days ago - Business Wire

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011...

16 days ago - Business Wire

Natera shares surge 17% after strong Q2 results and upgraded guidance

Shares of genetic testing company Natera (NASDAQ:NTRA) jumped sharply in morning trading, rising as much as 17% after the company reported better-than-expected second-quarter 2025 financial results an...

25 days ago - Invezz

Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript

Natera, Inc. (NASDAQ:NTRA) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Michael B. Brophy - Chief Fi...

26 days ago - Seeking Alpha

Natera Reports Second Quarter 2025 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. R...

26 days ago - Business Wire

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal ...

27 days ago - Business Wire

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transp...

4 weeks ago - Business Wire

Natera to Report Its Second Quarter Results on August 7, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30,...

4 weeks ago - Business Wire

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization...

5 weeks ago - Business Wire

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published fin...

5 weeks ago - Business Wire

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latit...

2 months ago - Business Wire

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical...

2 months ago - Business Wire

Natera Announces Medicare Coverage for Signatera™ Genome

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medica...

3 months ago - Business Wire

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assa...

3 months ago - Business Wire

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at...

3 months ago - Business Wire

Natera: The Clues In Q1 Earnings

Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signater...

3 months ago - Seeking Alpha

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

4 months ago - Seeking Alpha

Natera Reports First Quarter 2025 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. R...

4 months ago - Business Wire

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at...

4 months ago - Business Wire

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new...

4 months ago - Business Wire